Related Experiment Video
Updated: Feb 13, 2026

Biobanking of Human Aqueous and Vitreous Liquid Biopsies for Molecular Analyses
Published on: September 11, 2023
Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular
Vincent Plagnol1, Samuel Woodhouse1, Karen Howarth1
1Research and Development, Inivata Ltd, Granta Park, Cambridge, United Kingdom.
Abstract:
Circulating tumor DNA (ctDNA) analysis is being incorporated into cancer care; notably in profiling patients to guide treatment decisions. Responses to targeted therapies have been observed in patients with actionable mutations detected in plasma DNA at variant allele fractions (VAFs) below 0.5%. Highly sensitive methods are therefore required for optimal clinical use. To enable objective assessment of assay performance, detailed analytical validation is required. We developed the InVisionFirst™ assay, an assay based on enhanced tagged amplicon sequencing (eTAm-Seq™) technology to profile 36 genes commonly mutated in non-small cell lung cancer (NSCLC) and other cancer types for actionable genomic alterations in cell-free DNA. The assay has been developed to detect point mutations, indels, amplifications and gene fusions that commonly occur in NSCLC. For analytical validation, two 10mL blood tubes were collected from NSCLC patients and healthy volunteer donors. In addition, contrived samples were used to represent a wide spectrum of genetic aberrations and VAFs. Samples were analyzed by multiple operators, at different times and using different reagent Lots. Results were compared with digital PCR (dPCR). The InVisionFirst assay demonstrated an excellent limit of detection, with 99.48% sensitivity for SNVs present at VAF range 0.25%-0.33%, 92.46% sensitivity for indels at 0.25% VAF and a high rate of detection at lower frequencies while retaining high specificity (99.9997% per base). The assay also detected ALK and ROS1 gene fusions, and DNA amplifications in ERBB2, FGFR1, MET and EGFR with high sensitivity and specificity. Comparison between the InVisionFirst assay and dPCR in a series of cancer patients showed high concordance. This analytical validation demonstrated that the InVisionFirst assay is highly sensitive, specific and robust, and meets analytical requirements for clinical applications.
Insights
The InVisionFirst assay accurately detects low-frequency mutations in circulating tumor DNA (ctDNA) for cancer care. This highly sensitive and specific assay is validated for clinical use in profiling patients and guiding treatment decisions.
Area of Science:
- Oncology
- Genomics
- Molecular Diagnostics
Background:
- Circulating tumor DNA (ctDNA) analysis is crucial for cancer patient profiling and guiding targeted therapy decisions.
- Detecting low-frequency mutations (below 0.5% VAF) in ctDNA requires highly sensitive analytical methods for clinical utility.
- Objective assessment of assay performance necessitates rigorous analytical validation.
Purpose of the Study:
- To develop and analytically validate the InVisionFirst™ assay for profiling actionable genomic alterations in cell-free DNA.
- To assess the assay's sensitivity, specificity, and robustness in detecting various mutation types across a range of variant allele fractions (VAFs).
- To confirm the assay's suitability for clinical applications in cancer care.
Main Methods:
- Development of the InVisionFirst™ assay utilizing enhanced tagged amplicon sequencing (eTAm-Seq™) technology.
- Profiling of 36 cancer-associated genes for point mutations, indels, amplifications, and gene fusions in cell-free DNA.
- Analytical validation using patient samples (non-small cell lung cancer patients and healthy donors) and contrived samples with known VAFs, compared against digital PCR (dPCR).
Main Results:
- The InVisionFirst assay demonstrated high sensitivity: 99.48% for SNVs at 0.25%-0.33% VAF and 92.46% for indels at 0.25% VAF.
- Exceptional specificity (99.9997% per base) was maintained, with high detection rates at low VAFs.
- The assay successfully detected gene fusions (ALK, ROS1) and amplifications (ERBB2, FGFR1, MET, EGFR) with high sensitivity and specificity, showing strong concordance with dPCR.
Conclusions:
- The InVisionFirst assay is a highly sensitive, specific, and robust method for detecting actionable genomic alterations in ctDNA.
- The assay meets the analytical requirements for clinical applications, supporting its use in cancer patient profiling and treatment guidance.
- This validated assay enables reliable detection of low-frequency mutations, advancing precision oncology.
Related Concept Videos
Molecular Comparison of Gases, Liquids, and Solids
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Reliability and Validity
Cis-regulatory Sequences
Development of Analytical Methods
Data Validation
Key parameters for method validation include:

